JP2004515243A - サイレント抗ｃｄ２８抗体およびその使用 - Google Patents

サイレント抗ｃｄ２８抗体およびその使用 Download PDF

Info

Publication number
JP2004515243A
JP2004515243A JP2002549291A JP2002549291A JP2004515243A JP 2004515243 A JP2004515243 A JP 2004515243A JP 2002549291 A JP2002549291 A JP 2002549291A JP 2002549291 A JP2002549291 A JP 2002549291A JP 2004515243 A JP2004515243 A JP 2004515243A
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
mouse
igg3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002549291A
Other languages
English (en)
Japanese (ja)
Inventor
ツォー・ジェイ・ヤン
ヒントン・ポール
バスケス・マクシミリアノ
康一 田村
康之 東
信男 関
博嗣 上田
Original Assignee
藤沢薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 藤沢薬品工業株式会社 filed Critical 藤沢薬品工業株式会社
Publication of JP2004515243A publication Critical patent/JP2004515243A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002549291A 2000-12-14 2001-12-14 サイレント抗ｃｄ２８抗体およびその使用 Withdrawn JP2004515243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (1)

Publication Number Publication Date
JP2004515243A true JP2004515243A (ja) 2004-05-27

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002549291A Withdrawn JP2004515243A (ja) 2000-12-14 2001-12-14 サイレント抗ｃｄ２８抗体およびその使用

Country Status (18)

Country Link
EP (1) EP1341553A4 (ko)
JP (1) JP2004515243A (ko)
KR (1) KR20040020866A (ko)
CN (1) CN1272345C (ko)
AR (1) AR031924A1 (ko)
AU (2) AU2608602A (ko)
BR (1) BR0116686A (ko)
CA (1) CA2432736A1 (ko)
CZ (1) CZ20031909A3 (ko)
HU (1) HUP0400697A3 (ko)
IL (1) IL156262A0 (ko)
MX (1) MXPA03005327A (ko)
NO (1) NO20032542L (ko)
NZ (1) NZ526569A (ko)
PL (1) PL363239A1 (ko)
RU (1) RU2261723C2 (ko)
WO (1) WO2002047721A1 (ko)
ZA (1) ZA200305384B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519389A (ja) * 2010-02-18 2013-05-30 エフィミュヌ 抗ｃｄ２８ヒト化抗体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
CN114917185B (zh) 2016-10-21 2023-11-14 美国安进公司 药物配制品及其制备方法
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113692286A (zh) * 2019-03-14 2021-11-23 比昂生物制剂公司 一种用于免疫抑制的方法
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023532339A (ja) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519389A (ja) * 2010-02-18 2013-05-30 エフィミュヌ 抗ｃｄ２８ヒト化抗体

Also Published As

Publication number Publication date
MXPA03005327A (es) 2004-12-03
CN1489473A (zh) 2004-04-14
ZA200305384B (en) 2004-10-11
HUP0400697A3 (en) 2007-05-02
AU2608602A (en) 2002-06-24
RU2003121231A (ru) 2005-02-10
WO2002047721A1 (en) 2002-06-20
PL363239A1 (en) 2004-11-15
CN1272345C (zh) 2006-08-30
EP1341553A4 (en) 2004-07-28
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
CZ20031909A3 (cs) 2003-11-12
NO20032542L (no) 2003-08-07
EP1341553A1 (en) 2003-09-10
NO20032542D0 (no) 2003-06-05
BR0116686A (pt) 2003-12-30
CA2432736A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
AU2002226086C1 (en) 2006-03-09
AR031924A1 (es) 2003-10-08
KR20040020866A (ko) 2004-03-09
RU2261723C2 (ru) 2005-10-10
NZ526569A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
TWI708787B (zh) Pd-1促效劑抗體及其用途
KR100191152B1 (ko) Cd4 특이적 재조합 항체
JP6621778B2 (ja) ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
EP1654286B1 (en) Humanized anti-cd4 antibody with immunosuppressive properties
EP0617126A2 (en) Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
JP2004515243A (ja) サイレント抗ｃｄ２８抗体およびその使用
JP2002506420A (ja) 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
KR20080045765A (ko) 인터페론 알파 수용체-1에 대한 인체화 항체
JP2002540764A (ja) Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
AU2021311701A1 (en) Anti-CTLA-4 antibody and use thereof
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof
EP4406970A1 (en) Monoclonal antibody targeting tigit
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041124

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20050225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20050520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061102